<DOC>
	<DOCNO>NCT00002824</DOCNO>
	<brief_summary>RATIONALE : Inserting gene herpes virus person 's cell may improve body 's ability fight cancer make cancer sensitive chemotherapy use antiviral drug ganciclovir . PURPOSE : Phase I trial study effectivenesss gene therapy treat patient primary brain tumor .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Primary Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response stereotactically administer recombinant adenovirus vector carry herpes simplex virus thymidine kinase gene ( H5.010RSVTK ) follow intravenous ganciclovir patient recurrent malignant glioma . II . Estimate maximum tolerate dose H5.010RSVTK patient . III . Describe toxic effect H5.010RSVTK . IV . Assess efficiency gene transfer duration transgene expression patient . V. Assess quantitative qualitative glucose metabolic activity tumoral site positron emission tomography . VI . Analyze immunologic response adenovirus transduction patient . VII . Determine benefit toxicity multiple dos H5.010RSVTK patient resectable tumor . OUTLINE : This dose-finding study . All patient receive stereotactically inject H5.010RSVTK ( recombinant adenovirus vector contain herpes simplex virus thymidine kinase gene ) . Cohorts 3-6 patient receive escalate dos H5.010RSVTK maximum tolerate dose reach . Ganciclovir give third post-injection day . Patients unresectable tumor receive ganciclovir 14 consecutive day . Patients resectable tumor receive ganciclovir 7 consecutive day undergo craniotomy optimal debulking injection second dose adenovirus vector follow ganciclovir 14 day . Patients follow monthly survival . PROJECTED ACCRUAL : A total 18 patient ( 9 resectable tumor 9 unresectable tumor ) enter 3 year .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma , include : Anaplastic astrocytoma Glioblastoma Evidence recurrence MRI positron emission tomography despite primary treatment include radiotherapy without chemotherapy Stereotactically accessible tumor Solitary tumor prefer Largest tumor surgically accessible debulking multifocal disease Not adjacent optic chiasm brain stem No subependymal spread No herniation mark midline shift Consent autopsy require PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70 % 100 % Hematopoietic : Hematologic parameter normal Hepatic : Hepatic parameter normal ( less twice normal anticonvulsant ) Renal : Renal parameter normal Cardiovascular : No congestive heart failure No angina Other : No medical contraindication neurosurgery fluid injection brain No serious uncontrolled infection Negative pregnancy test require fertile woman prior entry Adequate contraception require fertile woman 3 month treatment PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 month since radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>